Meet Alex Grassin
I'm a CFO with 25 years in finance across the US and Europe, and I build the finance function biotech companies need to scale: the systems, processes, controls and the team to run them.
I trained in audit at KPMG Paris and held finance roles at Novartis and Alexion before moving into biotech leadership. As CFO of Genkyotex in Geneva (2012–2021), I led finance and every function outside R&D for nine years. I closed the company's private financings, executed its reverse takeover onto Euronext, served as public-company CFO for four years, and led the closing of its $87M sale to Calliditas through to delisting.
Since 2022, through Grassin Consulting, I've worked as fractional and interim CFO to biotech companies including HiFiBiO Therapeutics, Enodia Therapeutics and enGene: building finance functions, restructuring cost bases, and supporting financings and transactions. I work in English and French.

My Career
Fractional CFO - Grassin Consulting - Boston, MA, USA
2022
-
Present
Advisory practice providing fractional and interim CFO services to early-stage biotech companies: building the finance function and supporting financings and transactions. Clients include HiFiBiO Therapeutics and Aleva Neurotherapeutics, with engagements at enGene and Enodia Therapeutics through Danforth Advisors.
Fractional CFO - Grassin Consulting - Boston, MA, USA
2022
-
Present
Advisory practice providing fractional and interim CFO services to early-stage biotech companies: building the finance function and supporting financings and transactions. Clients include HiFiBiO Therapeutics and Aleva Neurotherapeutics, with engagements at enGene and Enodia Therapeutics through Danforth Advisors.
Fractional CFO / VP, Global Head of Finance - HiFiBiO Therapeutics - Cambridge, MA, USA
2023
-
Present
Clinical-stage biotech company with operations in the US, France and China, advancing antibody therapies for cancer and autoimmune diseases. ❖ Fractional CFO (2025–present): returned mid-restructuring and completed the company-wide restructuring (90 → 20 employees, ~$10M annual savings), including closing the Cambridge office and moving to CIC. ❖ Resolved legacy ESOP, intercompany and financial structure issues, restoring governance and audit readiness. ❖ VP, Global Head of Finance (2023–2024): built and led a global finance team and consolidated accounting and operations under the US headquarters. ❖ Directed IPO readiness and investor outreach.
Fractional CFO / VP, Global Head of Finance - HiFiBiO Therapeutics - Cambridge, MA, USA
2023
-
Present
Clinical-stage biotech company with operations in the US, France and China, advancing antibody therapies for cancer and autoimmune diseases. ❖ Fractional CFO (2025–present): returned mid-restructuring and completed the company-wide restructuring (90 → 20 employees, ~$10M annual savings), including closing the Cambridge office and moving to CIC. ❖ Resolved legacy ESOP, intercompany and financial structure issues, restoring governance and audit readiness. ❖ VP, Global Head of Finance (2023–2024): built and led a global finance team and consolidated accounting and operations under the US headquarters. ❖ Directed IPO readiness and investor outreach.
Interim CFO (Consultant through Danforth Advisors) - Enodia Therapeutics - Paris, France (remote)
2026
-
2026
Preclinical biotech (France, Belgium) developing small-molecule therapies that selectively degrade disease-driving proteins, starting with IO and I&I disorders. ❖ Built the finance function: budgeting, management reporting, systems, processes and governance across France and Belgium. ❖ Led business planning, cash runway and use-of-proceeds modeling to support financing strategy and investor discussions. ❖ Established the Belgian subsidiary and local finance infrastructure, including accounting resources and cross-border processes. ❖ Implemented equity incentive programs and D&O, key-person and broader insurance coverage. ❖ Handed over to the incoming CFO in October 2026; continuing to support the transition.
Interim CFO (Consultant through Danforth Advisors) - Enodia Therapeutics - Paris, France (remote)
2026
-
2026
Preclinical biotech (France, Belgium) developing small-molecule therapies that selectively degrade disease-driving proteins, starting with IO and I&I disorders. ❖ Built the finance function: budgeting, management reporting, systems, processes and governance across France and Belgium. ❖ Led business planning, cash runway and use-of-proceeds modeling to support financing strategy and investor discussions. ❖ Established the Belgian subsidiary and local finance infrastructure, including accounting resources and cross-border processes. ❖ Implemented equity incentive programs and D&O, key-person and broader insurance coverage. ❖ Handed over to the incoming CFO in October 2026; continuing to support the transition.
Interim CFO (Consultant through Danforth Advisors) - enGene inc - Boston, MA, USA
2022
-
2023
Clinical-stage biotech company with operations in the US and Canada, developing non-viral gene therapies; lead candidate targets non-muscle invasive bladder cancer (NMIBC). ❖ Interim CFO as part of the team that closed the $135M business combination with Nasdaq-listed Forbion European Acquisition Corp (FEAC), including PIPE, private investments and non-redemption commitments. ❖ Led modeling and reconciliation of complex cap table structures pre- and post-combination.
Interim CFO (Consultant through Danforth Advisors) - enGene inc - Boston, MA, USA
2022
-
2023
Clinical-stage biotech company with operations in the US and Canada, developing non-viral gene therapies; lead candidate targets non-muscle invasive bladder cancer (NMIBC). ❖ Interim CFO as part of the team that closed the $135M business combination with Nasdaq-listed Forbion European Acquisition Corp (FEAC), including PIPE, private investments and non-redemption commitments. ❖ Led modeling and reconciliation of complex cap table structures pre- and post-combination.
CFO - Aleva Neurotherapeutics - Lausanne, Switzerland
2021
-
2023
Swiss commercial-stage MedTech company with operations in Switzerland and Germany, developing deep brain stimulation (DBS) devices for neurological disorders such as Parkinson’s disease. ❖ Partnered with the CEO to lead the company's transformation from R&D to commercialization. ❖ Supported the closing of a $19M financing from family offices and strategic investors. ❖ Negotiated licensing deals and joint ventures in Europe and China.
CFO - Aleva Neurotherapeutics - Lausanne, Switzerland
2021
-
2023
Swiss commercial-stage MedTech company with operations in Switzerland and Germany, developing deep brain stimulation (DBS) devices for neurological disorders such as Parkinson’s disease. ❖ Partnered with the CEO to lead the company's transformation from R&D to commercialization. ❖ Supported the closing of a $19M financing from family offices and strategic investors. ❖ Negotiated licensing deals and joint ventures in Europe and China.
CFO / VP Finance & Administration - Genkyotex, Geneva, Switzerland
2012
-
2021
Clinical-stage biotech company (Phase 2) with operations in Switzerland and France, developing NOX enzyme inhibitors for fibrotic diseases including primary biliary cholangitis (PBC). ❖ Headed all non-R&D functions for 9 years and built the finance and administration team and processes. ❖ Closed three private rounds ($61M), a $9M convertible loan and a $5M rights offering. ❖ Main point person on the reverse takeover (RTO) with Genticel, leading to a public listing on Euronext Paris and Brussels. ❖ Served as public-company CFO for 4 years: reporting, governance and investor relations. ❖ Led the closing of the $87M sale to Calliditas via a block trade and mandatory tender offer, through to delisting.
CFO / VP Finance & Administration - Genkyotex, Geneva, Switzerland
2012
-
2021
Clinical-stage biotech company (Phase 2) with operations in Switzerland and France, developing NOX enzyme inhibitors for fibrotic diseases including primary biliary cholangitis (PBC). ❖ Headed all non-R&D functions for 9 years and built the finance and administration team and processes. ❖ Closed three private rounds ($61M), a $9M convertible loan and a $5M rights offering. ❖ Main point person on the reverse takeover (RTO) with Genticel, leading to a public listing on Euronext Paris and Brussels. ❖ Served as public-company CFO for 4 years: reporting, governance and investor relations. ❖ Led the closing of the $87M sale to Calliditas via a block trade and mandatory tender offer, through to delisting.
Business Controller - Alexion Pharma International - Lausanne, Switzerland
2010
-
2012
Business controller for Western Europe and headquarters at Alexion, a rare-disease biotech now part of AstraZeneca.
Business Controller - Alexion Pharma International - Lausanne, Switzerland
2010
-
2012
Business controller for Western Europe and headquarters at Alexion, a rare-disease biotech now part of AstraZeneca.
FP&A Manager - Novartis Consumer Health - Nyon, Switzerland
2007
-
2010
Business planning & analysis and reporting roles for the European OTC business of Novartis Consumer Health.
FP&A Manager - Novartis Consumer Health - Nyon, Switzerland
2007
-
2010
Business planning & analysis and reporting roles for the European OTC business of Novartis Consumer Health.
Accounting Manager/Financial Controller - Intrawest Europe - Lausanne, Switzerland
2004
-
2007
Head of accounting, then financial controller, for Intrawest's ski-resort real estate developments in the French Alps.
Accounting Manager/Financial Controller - Intrawest Europe - Lausanne, Switzerland
2004
-
2007
Head of accounting, then financial controller, for Intrawest's ski-resort real estate developments in the French Alps.
Senior Auditor - KPMG Audit - Paris, France
2000
-
2004
External audit at KPMG Paris over four audit seasons, progressing to Senior 2.
Senior Auditor - KPMG Audit - Paris, France
2000
-
2004
External audit at KPMG Paris over four audit seasons, progressing to Senior 2.
BIOTECH FRACTIONAL CFO
Let's get in touch
Need fractional CFO support or have questions?
I’m here to help you.
BIOTECH FRACTIONAL CFO
Let's get in touch
Need fractional CFO support or have questions?
I’m here to help you.
BIOTECH FRACTIONAL CFO
Let's get in touch
Need fractional CFO support or have questions?
I’m here to help you.